SK Bioscience announced on the 13th that its ‘SKYCovione’ has shown to have an effect in preventing the Omicron variant as a booster shot.

The company identified such results from an extension study on Phase I/II trial on SKYCovione that was conducted on 81 healthy adults who received a booster dose of SKYCovione around 7 months after primary vaccination.

Study results showed that the neutralizing antibody titres against the Omicron variant BA.1 were 25 times the titres right after the second dose, and 72 times the titres 7 months after the second dose (immediately before receiving a booster shot)

SKYCovione is a locally developed COVID-19 prevention vaccine that was ap